Meeting
2023 ASCO Genitourinary Cancers Symposium
Patient (pt) perspective on fatigue and its management for advanced prostate cancer (PC) treated with androgen receptor inhibitors (ARIs).
Authors
Stephen J. Freedland
Cedars-Sinai Medical Center, Durham VA Medical Center, Los Angeles, CA
Stephen J. Freedland , Marty Chakoian , Edward Wells , Nader N. El-Chaar , Alexandra Colon , Dina Elsounda , Agnes Hong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 100)
DOI
10.1200/JCO.2023.41.6_suppl.100
Abstract #
100
Poster Bd #
D14
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
First Author: Jian Guan
Poster
2023 ASCO Annual Meeting
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
First Author: Alicia K. Morgans
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).
First Author: Daniel J. George
Poster
2022 ASCO Genitourinary Cancers Symposium
Evaluation of tumor genomic variants in Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide: Protocol of a phase 4 study (CUARTET).
First Author: Hirotsugu Uemura